AstraZeneca (AZN) is a Healthcare company in the Drug Manufacturers General industry. It has a market capitalization of $289.14B, a trailing price-to-earnings ratio of 38.8 and a free-cash-flow yield of 3.0%. Over the most recent reported fiscal year, revenue grew 8.6% and free cash flow per share grew 19.2%. Nama's AI scorecard rates it Hold, 5.4 out of 10. On 12-month momentum it ranks in the rising band of its market.
AI scorecard
Hold · 5.4/10
The sections balance. As of Nov 7, 2026.
Momentum
Rising · +91.1% over 12 months ex. last
Second-best fifth of its market on the past year's move.
Shariah screen
Shariah Compliant
Passes our debt, cash and income screen; not a scholar's ruling.
Off its high
-12.3%
How far the last close sits under the highest price of the past five years.
Market cap
$289.14B
Trailing P/E
38.8
Price / book
5.8
Price / sales
4.6
FCF yield
3.0%
Dividend yield
1.7%
Gross margin
82.6%
Operating margin
24.0%
Net margin
17.5%
Revenue growth (YoY)
+8.6%
Revenue growth (3-yr annual)
+9.8%
EPS growth (YoY)
—
FCF/share growth (YoY)
+19.2%
Beta
0.2
Exchange
NYSE
Sector
Healthcare
Industry
Drug Manufacturers General
AZN earnings
Next report: Feb 9, 2027 (Q4 2026, EPS estimate $1.74).
Beat the EPS estimate in 3 of 4 recent quarters.
Quarter
Reported
EPS
Estimate
Surprise
Revenue
Q3 2026
Oct 30, 2026
$1.00
$1.15
-13.0%
$16.21B
Q2 2026
Jul 27, 2026
$1.32
$1.25
+5.6%
$15.38B
Q1 2026
Apr 29, 2026
$1.29
$1.27
+1.6%
$15.29B
Q3 2025
Nov 6, 2025
$1.19
$1.13
+5.3%
$15.19B
AZN analyst price target
Median target $208.00 from 12 analysts, ranging $158.00 – $240.00.
Nama's AI scorecard currently rates AstraZeneca Hold (5.4 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is AZN's P/E ratio?
AstraZeneca trades at a trailing price-to-earnings ratio of 38.8.
When does AZN report earnings?
AstraZeneca's next scheduled report is on Feb 9, 2027. Analysts expect EPS of $1.74.
What is the AZN price target?
The median analyst price target from 12 analysts is $208.00, with a range of $158.00 – $240.00.
Is AZN Shariah compliant?
Nama's AAOIFI-style screen reads AstraZeneca as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.